Equities

Sinovac Biotech Ltd

Sinovac Biotech Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments11,22311,31313,415
Total Receivables, Net451609952
Total Inventory140181376
Prepaid expenses1215161
Other current assets, total5.178.2511
Total current assets11,83112,12614,915
Property, plant & equipment, net1,0251,0521,019
Goodwill, net------
Intangibles, net8.529.701.48
Long term investments684661656
Note receivable - long term------
Other long term assets1412465
Total assets13,65814,11516,748
LIABILITIES
Accounts payable172059
Accrued expenses258250537
Notes payable/short-term debt000
Current portion long-term debt/capital leases764.654.68
Other current liabilities, total7978171,813
Total current liabilities1,1481,0922,413
Total long term debt1781217
Total debt2541622
Deferred income tax264242324
Minority interest3,3133,7914,549
Other liabilities, total4657118
Total liabilities4,9495,1937,421
SHAREHOLDERS EQUITY
Common stock0.100.100.10
Additional paid-in capital541541541
Retained earnings (accumulated deficit)8,6588,7648,656
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(490)(383)131
Total equity8,7098,9219,327
Total liabilities & shareholders' equity13,65814,11516,748
Total common shares outstanding100100100
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.